Clinical characteristics of hyperprogressive disease in NSCLC after treatment with immune checkpoint inhibitor: a systematic review and meta-analysis

BACKGROUND: A number of studies have reported hyperprogressive disease (HPD) in non-small cell lung cancer (NSCLC) after treatment with immune checkpoint inhibitor (ICI). This study aimed to summarize the incidence and survival outcome of HPD in NSCLC and identify the clinicopathological features as...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yan, Hu, Junjie, Bu, Fangfang, Zhang, Haiping, Fei, Ke, Zhang, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392646/
https://www.ncbi.nlm.nih.gov/pubmed/32727409
http://dx.doi.org/10.1186/s12885-020-07206-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392646/
https://www.ncbi.nlm.nih.gov/pubmed/32727409
http://dx.doi.org/10.1186/s12885-020-07206-4

Ejemplares similares